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Abstract: Prion, or PrPSc, is the pathological isoform of the cellular prion protein (PrPC) and it
is the etiological agent of transmissible spongiform encephalopathies (TSE) affecting humans and
animal species. The most relevant function of PrPC is its ability to bind copper ions through its
flexible N-terminal moiety. This review includes an overview of the structure and function of PrPC
with a focus on its ability to bind copper ions. The state-of-the-art of the role of copper in both
PrPC physiology and in prion pathogenesis is also discussed. Finally, we describe the structural
consequences of copper binding to the PrPC structure.
Keywords: prion protein; copper binding; copper coordination geometries; neurodegenerative
diseases
1. Introduction
Prion diseases or transmissible spongiform encephalopathies (TSEs) are fatal neurodegenerative
disorders that affect humans and a wide range of mammalian species. These disorders can arise
sporadically, be inherited, or be acquired through infection. The sporadic forms are the most
common and in humans sporadic prion diseases account for approximately 85% of all cases [1].
They include sporadic Creutzfeldt–Jakob disease (sCJD) [2], sporadic fatal insomnia, and the variably
protease-sensitive prionopathies [3]. Genetic forms of prion diseases are associated with mutations in the
human prion protein gene (PRNP) and comprise familial CJD (fCJD), Gerstmann–Straussler–Scheinker
(GSS) syndrome [4], fatal familial insomnia (FFI) [5] and prion protein cerebral amyloid angiopathy [6].
Acquired prion diseases are very rare, occurring in less than 1% of the cases. They are transmitted from
human to human, as iatrogenic CJD and Kuru, or from cattle to humans, as variant CJD (vCJD) [7].
Animal TSEs are scrapie in sheep and goats, bovine spongiform encephalopathy (BSE) in cattle and
chronic wasting disease (CWD) in deer, elk and moose [8]. BSE spread from the UK to at least 28 other
countries, mostly in Europe, with occasional cases also confirmed in Asia and North America, while
CWD has slowly spread around 26 states in the United States of America, as well as 3 provinces in
Canada and in South Korea [9,10]. Notably, the first European cases of CWD have been recently
identified in free-ranging reindeer, moose and red deer in Norway, Finland, and Sweden [11–14].
Interestingly, a first case of dromedary camel prion disease (CPD) has been recently reported in
Algeria [15].
The neuropathological hallmarks of TSEs are spongiosis, glial proliferation, and neuronal loss.
They are caused by the misfolding of the physiological cellular prion protein (PrPC) into its pathogenic
scrapie isoform (PrPSc), an insoluble and partially protease-resistant isoform that is able to propagate
by interacting to and converting PrPC into nascent prion molecules [16].
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PrPC is a ubiquitous glycosylphosphatidylinositol (GPI)-linked glycoprotein, highly conserved
among mammals [17], mainly found in the central and peripheral nervous systems [18,19]. As a typical
cell-surface glycoprotein, the pre-pro-protein is synthesized in the endoplasmic reticulum (ER), due to
the presence of a 22 amino acids N-terminal signal peptide that is then cleaved into the ER lumen. Here,
the immature prion protein is subjected to several post-translational modifications including N-linked
glycosylation, formation of a disulfide bond, cleavage of the C-terminal signal peptide and subsequent
attachment of the GPI anchor at position 231 [20–22]. The mature GPI-anchored form, PrPC, is trafficked
through the Golgi apparatus where further processing of the N-linked oligosaccharides results in
modified glycosylation to complex-type sugar chains, depending on the number of glycosylation
sites occupied with oligosaccharide chains [23]. The mature PrPC is found mostly in the cholesterol-
and sphingolipid-rich membrane domains, also known as lipid rafts, which are detergent-resistant
membrane domains with many important cellular receptors and other GPI-anchored proteins [24].
2. The Structure of PrPC and PrPSc
After attachment to the outer leaflet of the plasma membrane via a C-terminal GPI anchor, the
mature PrPC consists of 209 residues including up to two N-linked glycans at asparagines 181 and
197 (human numbering). Atomic structures obtained by NMR techniques and X-ray crystallography
revealed that PrPC shares a very similar fold across different mammalian species. The globular
C-terminal domain of PrPC (residues 128–231) contains three α-helices (α1, α2 and α3) and two
short anti-parallel β-sheets (β1 and β2) [25]. Recently, an additional short β-sheet (denoted as β0)
has been identified [26]. Helices 2 and 3 are covalently bridged by a single disulfide bond between
Cys179 and Cys214, essential in forming and maintaining the tertiary fold. The N-terminal domain
of PrPC (from residue 23 to 127) is largely unstructured [27] and it is composed of four different
consecutive domains, or octapeptide repeats (OR) (residues 60–91), each carrying histidines and
tryptophan able to coordinate up to four copper ions with different coordination geometries and high
affinity [28]. Additional histidines (His96 and His111) are able to bind copper, they are located in the
“fifth” or non-OR copper binding site (residues 92–111) [29]. The adjacent region is a hydrophobic
domain that includes the palindromic motif of sequence AGAAAAGA (residues 113–120), which is
thought to play a role during prion conversion [30]. PrPC can also undergo proteolytic processing [31].
The alpha-cleavage is the main proteolytic event of PrPC. It is located at His111 and leads to the
production of two fragments: the N-terminal fragment, N1 (23–110 residues) and a C-terminal fragment,
C1 (111–231) [32].
Unlike PrPC, the PrPSc structure features mostlyβ-sheet secondary structure motives. These unique
structural features of PrPSc are responsible for its physicochemical properties, including insolubility in
non-ionic detergents, partial proteinase-K (PK) resistance, and aggregation propensity [33]. Its insoluble
and heterogeneous nature renders its structural characterization extremely difficult. To date several
prion structural models have been proposed, two of them seem to be the most accepted: the parallel
in-register intermolecular β-sheet (PIRIBS) and the 4-rung β-solenoid models [34,35]. The 4-rung
β-solenoid model is in agreement with experimental constraints of brain derived PrPSc obtained
through cryo-EM and X-ray fiber diffraction studies [36,37] and allows accommodation of the bulky
glycans present in brain-derived PrPSc [38]. On the other hand, the infectious PrP23–144 amyloid [39]
exhibits a PIRIBS architecture, and solid-state NMR studies revealed structural differences between
PrP23-144 amyloid fibrils from different species, providing a structural basis for understanding the
species barrier phenomenon [40,41].
3. PrPC Functions Suggested by Copper Binding
The most well-known function of PrPC is its ability to bind metal ions through its flexible
N-terminal moiety. Since the first observation of PrPC as a copper-binding protein [42], many attempts
have been made to understand the role of metal ions in both PrPC physiology as well as in prion
pathogenesis. Indeed, the molecular details of PrPC metal binding are now well understood. In contrast,
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the effects of metal binding on the in vivo function of PrPC are largely unknown, in part due to the
complexity of the metal metabolism and because the interaction of proteins with metals is often missed
due to low affinity or their transient nature [43]. Nevertheless, to date evidence supports the idea that
the physiological function of PrPC is related to its metal-binding properties.
A role for Cu(II)-binding PrPC in stimulating endocytosis and trafficking of PrPC, acting as a
copper uptake protein has been suggested [44–48]; other investigations propose a role for PrPC as
an antioxidant, with a copper-dependent enzyme function with SOD-like activity [49]. PrPC is also
involved in neuritogenesis [50] through its N-terminal domain [51]. This may be correlated to its role
in memory and cognition synaptic regulation [52].
Other studies proposed PrPC functions attributed to the PrPC ability to bind copper are related to
N-methyl-d-aspartate (NMDA) receptors modulation [53–55] and brain metal homeostasis [56]. Some
others point out the role of Cu(II) either as promoter or attenuator of β-sheet conversion and amyloidal
aggregation [57–60].
PrPC binds copper in vivo [61] and cultured murine cells and neurons chronically exposed to high
Cu(II) concentrations show increased expression of Prnp [62]. It was shown that the addition of copper
significantly increased PrPC levels in neuronal cells, while the co-treatment with bathocuprionedisulfate
(BCS), a copper chelator, re-established normal PrPC expression levels.
It has also been reported that copper stimulates rapid endocytosis and trafficking of PrPC,
functioning as a copper uptake protein [44–48]. PrPC is predominantly localized to presynaptic
membranes, where copper ions are highly localized [45]. Lower copper concentration in synaptosomal
preparations of Prnp0/0 mice suggest that PrPC plays a role in regulating copper concentration at the
synapse of neurons as well as in the re-uptake of the metal into the presynaptic cleft [47]. Furthermore,
copper added to cultured neuroblastoma cells promotes the endocytosis of the PrPC [44,46]. Therefore, it
can be hypothesized that the transport of copper from the extracellular to the intracellular compartment
is operated through PrPC internalization. Alternatively, PrPC may act as a copper buffering molecule
at the synaptic cleft, capturing copper and handling it over to other membrane transporters. By using
PrPC mutants lacking either the OR region or the N-terminal polybasic region, Taylor et al. shown that
copper binding to the OR promotes dissociation of PrPC from lipid rafts towards detergent-soluble
regions of the plasma membrane, while the N-terminal polybasic region mediates its internalization by
clathrin-mediated endocytosis [63].
An evolutionary relationship between PrPC and ZIP (Zrt-, Irt-like Protein) family of zinc
transporters supports the function of PrPC in relation with its metal ion regulation [64]. Indeed,
it has been shown that PrPC regulates the amount and distribution of specific metals within the central
nervous system, thus regulating the progression of neurodegenerative diseases in which altered metal
homeostasis might have a role in Alzheimer’s and Parkinson’s diseases [56]. Pocanschi et al. suggest
that ZIP5 was found to have the same subcellular locations as PrPC, when expressed in neuroblastoma
cell lines [65]. Interestingly, they found that ZIP5 undergoes N-glycosylation within its PrP-like domain,
and it may acquire a dimeric, globular fold similar to that of mammalian PrPC [65]. The observed
co-localization between PrPC and ZIP5 might indicate that the two proteins have retained, throughout
evolution, features responsible for their subcellular localization [65].
Consistently with PrPC localization in the synaptic region together with its high affinity to copper
ions, PrP is thought to possess a copper-dependent enzyme function with SOD-like activity, enabling
its effective function as an antioxidant in the central nervous system [49]. Mouse PrPC either as
recombinant protein or immunoprecipitated from brain tissue has been shown to have the activity of a
copper/zinc-dependent superoxide dismutase (SOD), endowing PrPC with antioxidant capacities [66].
In vivo studies show that the activity of cytosolic SOD is reduced in the brains of PrP-knock out (KO)
mice [49], while increased in mice that overexpressing PrPC [67]. Moreover, SOD activity in brain
lysates from WT mice was reduced after PrPC removal using anti-PrPC antibodies [68]. However,
studies with PrP-KO mice show decreased SOD activity, without increased susceptibility to oxidative
stress [67], while other studies have shown that PrP does not exhibit SOD-like activity in vivo nor
Cells 2019, 8, 770 4 of 17
in vitro [69,70]. Although the role of PrPC as a SOD or as an oxidative stress-reducer is not yet definitive,
PrPC clearly has a neuroprotective role.
Additional evidence about physiological functions of PrPC arise from studies on deletions in
the N-terminal domain showing that PrPC may protect against excitotoxic stress in neurons. While
the deletion of the entire N-terminal domain has no clinical symptoms or neuropathology [71],
removing 21 residues (105–125) from the N-terminal domain of PrP (PrP ∆CR) induces spontaneous
neurodegeneration in transgenic mice, without accumulation of PrPSc [72,73]. Interestingly, this
neurotoxic phenotype can be suppressed by co-expressing WT PrPC [74,75], suggesting that WT and
deleted PrPC might interact with each other or by competing for a binding to a specific molecule at the
cell surface.
PrPC has been also considered as a neurotrophic factor that facilitates neurite outgrowth and
growth cone (GC) guidance through NCAM-Fyn-ERK pathway [76,77]. This process is clearly inhibited
if the copper binding site is disrupted with a consequent altered copper coordination [51].
It has also been established that PrPC regulates N-methyl-d-aspartate receptor (NMDAR),
protecting neurons from glutamate-induced excitotoxicity [54,55,78,79]. Impairments in NMDAR
activity induces excitotoxicity in PrP-KO mice causing massive calcium influx thus leading to neuronal
cell death pathway. Co-expression of PrPC WT allows PrPC to inhibit the NMDAR, leading to suppress
excitotoxicity [54]. This process requires the presence of copper. Interestingly, this protective role of
PrPC is consistent with recent studies, in which overexpression of mouse PrPC induces desensitization
of NMDA currents, while overexpression of human PrPC had an opposite effect, suggesting that the
NMDA receptor could be differentially sensitive to the conformation structure adopted by human
and mouse PrPC [80]. Gasperini et al. showed that PrPC exerts copper-dependent neuroprotection
by inhibiting NMDAR through S-nitrosylation, a post-translational modification resulting from the
reaction of nitric oxide (NO) with cysteines [53]. In particular, they found that NMDAR S-nitrosylation
decreased in PrP-KO mice and copper chelation decreases NMDAR S-nitrosylation in WT but not in
PrP-KO mice. They proposed a neuroprotective mechanism of PrPC, in which PrPC-bound copper ions
act as electron acceptors in the reaction between NO and NMDAR cysteine thiols. The consequent
S-nitrosylation inhibits the NMDAR, leading to a reduction of the neurotoxic effect caused by its
overactivation. In a subsequent study, the NMDAR S-nitrosylation levels were analyzed at pre- and
post-symptomatic stages of mice intracerebrally inoculated with RML, 139A, and ME7 prion strains [81].
It was found a reduction of the levels of NMDAR S-nitrosylation at both pro- and pre-symptomatic
stages, suggesting an impairment of NMDAR S-nitrosylation as a mechanism causing neuronal death
in prion diseases. Therefore, the progression of excitotoxicity might be blocked by restoring NMDAR
modulation and preventing neuronal loss thus opening the possibility for new therapeutic approaches
against prion disorders [81]. These findings underlined the role of Cu-bound to PrPC in neuroprotective
mechanisms, which could be altered by the presence of ligand that interfere with copper binding, as
the case of amyloid-β (Aβ) that might mediate neuronal and synaptic injury by disrupting the normal
NMDAR activity [82].
The PrP metal-binding property has been used to purify recombinant prion protein [83,84] as well
as natively folded PrPC isolated from brain tissue [85–88] by using Cu(II)-loaded immobilized metal
affinity chromatography (IMAC) columns, as the PrP copper binding sites work as an affinity tag for
such columns, thus enabling one-step purification of proteins without the use of histidine tag [83].
Interestingly, the ability of PrPC to bind Cu(II)-loaded IMAC columns is strongly dependent on the
glycosylation state of the protein [89]. The non-glycosylated form of the full-length PrP has the highest
binding affinity for metal ions among the different PrP glycoforms. The fact that either one of the two
glycans are sufficient to alter the metal ion-binding capacity of PrP might be correlated to the presence
of interactions between the C-terminal located glycans and the N-terminal domain.
Although it was proposed that PrPSc was not able to bind copper immobilized on Cu(II)-loaded
IMAC [87,88], Dron and colleagues have shown that the ability of PrPSc to bind copper ions has
allowed the biochemical characterization of different truncated forms of PrPSc, whose binding affinity
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dramatically depended on which cell or tissue supported prion replication [90]. Furthermore, it was
shown that copper enhances the recovery of both PrP infectivity and PK resistance in samples that
did not renature by diluting guanidine hydrochloride, probably by stabilizing the formation of initial
aggregates. It might well be that copper promotes the formation of defined structures in PrP monomers
and modulates interactions between PrP monomers [91,92].
All PrPC functions involving Cu(II) binding are listed in Table 1.
Table 1. PrPC functions suggested by Cu(II) binding.
Cu(II)-Mediated Function Experimental System Reference
Endocytosis and trafficking Cell culture, mice [44–48,63]
Superoxide dismutase-like activity Cell culture [49]
Neuritogenesis Primary hippocampal cultures [51]
N-methyl-d-aspartate (NMDA) receptors modulation Organotypic hippocampal culture,primary cell culture, mice [53–55,80–82]
Brain metal homeostasis Cell culture, mice [56]
Inducing or inhibiting β-sheet conversion and
amyloidal aggregation
Recombinant mouse prion protein,
recombinant human prion protein [57–60]
Increasing expression of Prnp Cell culture, primary cell culture [62]
One-step purification by using Cu-loaded IMAC
column
Recombinant prion protein, brain
tissues [85–87,93]
Enhanced reversibility of scrapie inactivation Mice [91]
4. Copper-Binding Models
The first observation of PrPC as copper-binding protein has been done by Hornshaw and
collaborators [42]. Thenceforth, elucidating the molecular details of copper binding has become of
utmost importance for better understanding the role of the copper in PrPC physiology and in the prion
pathogenesis. PrPC primarily binds copper through the OR region composed of multiple tandem
repeats of the eight-residue sequence PHGGGWGQ (Figure 1). Across species, the OR domain is
the most highly conserved regions of PrPC sequence, even if some species carry four or five OR
repeats [94]. Although X-ray crystallography and solution-state NMR are the canonical approaches for
structural determinations, each of them encounters technical problems due to the presence of copper.
For example, the presence of paramagnetic Cu(II) in NMR leads to significant line broadening [95].
To overcome these problems, a wide range of electron paramagnetic resonance (EPR) methodologies
have been explored to study the structural features and affinities of the Cu(II) to the OR [96]. By using
EPR analysis of a series of octarepeat peptides, it was shown that the octarepeat domain takes up four
equivalents of copper, in which the coordination environment is composed of three nitrogen atoms
and one oxygen atom. The residues HGGGW in each repeat represent the fundamental Cu(II)-binding
unit [97]. Then, by using a library of site specifically 15N-labeled octarepeat peptides, it was shown that
the two glycine (Gly) residues following the His coordinate through their amide nitrogens, while the
14N of the third Gly is not coordinated to the Cu(II) center, being 4.0 Å away. These EPR experiments
are in agreement with the X-ray crystal structure of the Cu(II)-HGGGW complex [98] which indicate a
square pyramidal geometry, as well as with subsequent computational [99] and NMR studies [100].
The EPR methodologies shown that the molecular features of copper coordination in the octarepeat
domain depend on the amount of copper bound [101]. Three different binding components at pH 7.4
were identified. Component 3 represents the low-occupancy mode of interaction with multiple His
residues coordinated a single Cu(II) with high affinity (as indicated by the dissociation constant (Kd)
of 0.1 nM). In contrast, higher copper occupancy -corresponding to the component 1 mode- involves
coordination through deprotonated amide nitrogens and exhibits a weaker affinity with a Kd of 10
µM. The intermediate state is represented in the component 2, where each Cu(II) coordinates two His
residues, thus forming intervening loops. It has been suggested that the OR domain does not play a role
in TSEs, since treatment with protease-K (PK) removes the OR regions without loss of infectivity [102].
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Moreover, it was shown that addition of copper to PrPC converts the protein to a partially PK-resistant
state, and this conversion requires only a single Cu binding site [103].
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Studies by Qin’s [104] and Millhauser’s groups [97] showed that another Cu binding takes place
outside the OR region, called non-OR or fifth copper-binding site, involving His96, which is adjacent
to the octarepeats and, like the octarepeats, is in a glycine rich environment (Figure 1). By using
circular dichroism to detect copper binding in peptides including His111, Jones et al. [57] showed
that both His96 and His111 bind copper. In particular, they found three coordination modes there
were strongly influenced by pH. All of them display a square planar geometry. At pH 7.5 and above,
a 4N complex dominates, while at pH 6.0, a ligand rearrangement shifts the coordination to a 3N1O
configuration. At low pH, a multi-histidine residue 2N2O coordination dominates. In line with this, it
was concluded that His96 and His111 bind copper independently, except at lower pH where both His
residues coordinate a single copper atom. The involvement of both His96 and His111 has also been
confirmed by NMR studies [59,105] as well as by analysis of metal catalyzed oxidation [106]. Data
suggest that His96 is the key site involved in copper binding [107]. Importantly, it was shown the
existence of a cooperative effect between Cu(II) binding to the N-terminus and to the non-OR copper
binding site that is mainly provided by His96 [107]. However, a recent spectroscopic study suggested
that the His111 has a slightly higher affinity for Cu(II) than His96, with Met109 playing a key role in
the binding preference of Cu(II) for the His111 site [108].
The role of copper binding to the OR and non-OR regions was also investigated by a combination
of genomic and cell biological approaches, and a focal stimulation technique. Here, by substituting
histidine residues with tyrosine located in the OR and non-OR region, alteration of the copper-binding
sites perturbed the PrPC structural conformation, thus failing to induce neurite outgrowth signal [51].
By using different spectroscopic techniques, studies have also focused on the Cu(II) coordination
to the C1 fragment, which includes the His111, as result of the neuroprotective alpha-cleavage [109].
By using the PrP(111–115) fragment as a model system, it was shown that the His111 and the free
NH2 group act as an anchoring site for Cu2+, resulting in different coordination modes, depending on
proton and copper concentrations ([109] and reviewed in [110]).
Interestingly, several studies suggest another copper-binding site located in the C-terminal domain
of PrPC. By using a series of His/Ser mutants of the C-terminal His residues, only H140S mutant
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remained folded in the presence of copper, but no relevant changes in copper binding were observed.
The same behavior was observed for H177S mutant for which no change in copper binding was shown.
Therefore, the authors proposed H187 as putative copper binding site [111–113]. Interestingly, H187 is
the site of a pathogenic mutation causing GSS-like disease in humans [114]. However, it seems that
copper binding in the C-terminal domain occurs only at very high copper levels, which is unlikely to
be physiologically relevant. This suggest a predominant, high-affinity copper coordination to PrPC
restricted to the N-terminal domain of PrPC [97].
5. Copper and Prion Diseases
A connection between prion disease and copper metabolism was first proposed in the early
1970s. Pattison and Jebbett [115] showed that a copper chelator, cuprizone, induces spongiform
encephalopathy and gliosis, similar to the histopathology observed in mouse scrapie. The work of
Kimberlin and Millson also found that cuprizone could delay (with very low inoculation titers) the
terminal illness in mice affected by scrapie [116]. After those studies, the issue seems to have been
largely overlooked for about two decades. The relationship between copper and prion diseases came
back into hot debate in 1997 when copper was found to bind PrPC [117]. There are still controversial
conclusions about the deleterious or beneficial effects of copper in prion diseases. Several studies
strongly support a beneficial role of copper against prion disease progression. It was showed that
supplementing copper in the diet prolonged the survival time in infected animals [118,119]. Moreover,
N2a cells treated with copper do not bind and internalize PrPSc [119]. Other groups suggest that copper
treatment interferes with the propagation of PrPSc in ScN2a cell lines while there is an accumulation
of total PrPC [120]. Instead, Sigurdsson and colleagues found that treatment of scrapie-infected
mice with a copper chelator delayed the onset of prion disease, suggesting that copper has a prion
promoting effect [121]. Additionally, copper has been found to convert PrPC into protease-resistant and
detergent-insoluble forms [103]. Fluorescence experiments show that Cu(II) promotes PK resistance
through direct interaction with PrP(23–231) and not by inhibiting PK itself as the truncated PrP(90–231)
exposed to Cu(II) remains more PK-sensitive. Moreover, only the full-length PrP exposed to Cu(II) ions
act as seed for the formation of PrP aggregates in vitro in the RT-QuIC seeding assay [122]. The effect of
Cu(II) binding on the fibrillization reaction has been also investigated recently by Qi et al. They found
that fibrillization does not abolish the ability of PrP to bind Cu(II) in both monomeric and fibrillar
forms. Furthermore, it seems that fibrillar form of PrP is no longer able to bind copper at the His96,
suggesting that somehow this region becomes inaccessible in the fibrillar state [123].
Consistently, a study on PrP expressed in yeast showed that supplement of copper in the yeast
growth media leads to the formation of PK-resistant forms [124]. A misfolding cyclic amplification
(PMCA) study showed that PrPSc in the presence of copper could propagate and form more prions in
the presence of deoxycholic acid [125]. Similar but contrasting results come from a study showing that
copper inhibits PrPC to PrPSc conversion in PMCA [126] as well as formation of fibrils from recPrP in
an amyloid seeding assay [120]. The latter study is in line with another RT-QuIC assay in which the
inhibition of fibril formation of recombinant elk PrP seems to be correlated to the presence of copper
ions in the reaction [127].
Wadsworth and colleagues have investigated the metal-ion occupancy in PrPSc isoform isolated
from two biochemically distinct strains of sporadic CJD [128]. By using metal-chelating agents to
disrupt PrPSc copper and zinc binding sites, they found an altered electrophoretic mobility of the
cleavage products after PK digestion in two of the four defined strains of CJD. Therefore, the authors
suggested that the ability of metal ions to influence PrPSc conformation could have implications for
understanding molecular mechanism for strain variation [128].
In vivo studies suggest that the absence of the octapeptide repeats still sustains scrapie infection,
but with longer incubation times without histopathological signs of scrapie [129]. Moreover, it was
shown that PrP fragments with larger deletions that included both OR and non-OR regions caused
spontaneous ataxia and degeneration of the granular layer of the cerebellum, highlighting the role
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of copper binding sites in prion conversion [130]. In contrast, a previous study revealed that the
deletion of an octarepeat did not lead to disease [131]. Insertion of nine extra octapeptide repeats in
the Prnp gene is associated with prion diseases as well [132]. Interestingly, Tg(PG14) mice expressing
nine-octapeptide insertion in PrP, thus resembling the human familial prion disease, spontaneously
developed a fatal neurodegenerative disorder, but they were characterized by the accumulation in the
brain of weakly protease-resistant form of PrP mutant which was not infectious in animal transmission
experiments [133].
The studies discussed above clearly show that there is a debate about the role of the copper in
facilitating or inhibiting prion formation. Additional studies are required to further investigate the
relationship between copper and prion diseases.
6. Structural Consequences of Copper Binding
Although the PrPC N-terminal and C-terminal moieties have often been described as independent
domains, several studies now suggest that copper ions promote specific N- to C-terminal interactions.
A recent study showed that copper bound to OR and non-OR regions induce major changes in the
interdomain conformation of the protein and proposed that the non-OR region acts as anchor of the
two halves of the protein [134]. Previously, Thakur et al. reported novel long-range inter-domain
interactions of the N- and C- terminal regions of full length recPrP upon Cu(II)-binding, resulting in
significant compactness of recPrP structure upon Cu(II)-binding. In particular, they found that the
region 90–120, containing the binding site His96 and His111, becomes proximal to the α1-helix for
interaction upon copper binding [58]. Subsequent EPR and NMR studies showed that Cu(II)-binding
to the OR region alters residues located nearby the β1-α1 loop and the α2-α3 loop region [135,136].
Recently, the same authors have identified the residues-level contacts between the N-terminal polybasic
domain (including the segment 23-31 and the non-OR region) and a C-terminal negatively charged
epitope coincident with the α1-β2-α2 loop region as well as the end of α3, detailing how the contacts
are altered by binding of Cu(II) [134].
The influence of copper ions on structural rearrangement of octarepeat regions from human and
chicken PrP has been also investigated [137]. In the presence of sodium dodecyl sulfate (or SDS) to
mimic the membrane environment in vitro, authors observed different copper coordination modes
in both human and chicken OR sequences. While three histidines are involved in binding for the
human OR, the binding involves four histidines for the chicken OR, suggesting that the aromatic ring
of tyrosine residues present in the chicken OR sequence may stabilize copper anchoring site [137].
Interestingly, both human and chicken OR regions were found to bind copper ions more efficiently
than the corresponding amyloidogenic fragments, probably due to the presence of four histidines
compared to the two histidines in the amyloidogenic sequence [138].
It has also been studied the effect of the pathological point mutations on copper coordination
when the metal is bound only to the non-OR region. By means of X-ray absorption spectroscopy,
D’Angelo et al. highlighted a significant modification of the non-OR Cu(II) binding site caused by the
pathological point mutation Q212P, located in the globular domain, reinforcing the hypothesis that the
non-OR copper binding site is strongly influenced by the interactions between the C- and N-terminal
domains [139]. The involvement of H96 and H111 in non-OR region shows that Cu(II) occupancy plays
a role in determining the conformation of PrPC. It was observed an alteration of Cu(II) coordination due
to the presence of a mutation that abrogates a copper ligand, H96Y, and causes spontaneous PrPSc-like
formation in neuronal cultured cells and accumulation in the acid compartments [140]. The authors
proposed a model whereby HuPrP coordinating copper with His96 and His111 in the non-OR region is
more resistant to prion conversion compared to the protein coordinating Cu(II) with one histidine [140]
(Figure 2). Molecular dynamic simulations also revealed alterations of hydrogen bond network in PrPC
coordinating one His, thus creating favorable conditions for transient β-sheet motif formations [140].
The effect of Cu(II)-binding was also assessed on the oligomerization of PrPC. Lin et al. showed that
Cu(II)-binding promoted oligomerization of a susceptible species more significantly than that of a
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resistant species, suggesting that the low susceptibility to Cu(II) in the resistant species might results
in a weak risk of Cu(II)-induced TSE diseases [141]. In support to the role of the non-OR region for
prion conversion, transgenic mice, TgPrP(H95G), with an amino acid replacement at residue H95
showed shorter disease progression than WT control mice and classical clinical signs of TSE [142].
Evidence about the role of copper ions in mediating structural changes of the N-terminal domain of
PrPC come from a work by Lu et al. By using the PrP(23-89) peptide, it was shown that Cu(II) induces
the formation of PK-resistant material detected by western blot and atomic force spectroscopy (AFM),
and structural changes detected by hydrogen/deuterium exchange in the N-terminus of PrPC [143].
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Cu(II)-binding t th non-OR regi n involving the His96 and His111 residues [140].
7. Conclusions
The link between PrPC and copper is likely to elucidate PrPC function, but also to provide
important new insights into the molecular basis of prion diseases. The N-terminal PrPC domain binds
copper ions through the OR and non-OR domains and this binding yields a diverse range of Cu(II)
coordination modes, each with a distinct binding affinity and geometry [28,139,140]. In this review we
have highlighted how copper displays site-specific effects on PrPC folding either promoting stabilizing
interactions [58] or inducing local conversion to beta-sheet folds [140]. While the atomic details of
Cu(II)-mediated structural changes remain to be fully understood, convincing evidence indicates
that copper mediates stabilizing interactions between the N-terminal and the C-terminal domains
leading to a compact PrPC folding [134]. Although the functional implications of this Cu(II)-mediated
structural change remain to be investigated, this interdomain interaction may play an important role in
the physiological activity of PrPC consistent with a proposed role for the protein as transporter, sensor
of divalent metal ions and NMDA receptor modulator [53,55,144].
The role of copper in TSE needs to be defined by conciliating both in vitro and in vivo observations.
Cu(II)-induced changes of PrPC folding observed in vitro and experiments in animal models suggest
a role of copper as a prion-promoting element; o the other hands experiments in cell and animal
models report the opposite. As mentioned, treatments of scrapie infected mice with copper chel tor
delayed he TSE onset and reduced copper levels in brain and blood, thus supporting t e notion that
copper exerts a prion promoting effect [121]. An opposite result showed that copper administration
to scrapi -infected hamsters delayed the onset of prion disease [119]. In upport to the proposed
beneficial role of copper agai st prion disease progression, different studies re orted that copper
treatment in scrapie-infected N2a cells interferes with prion propagation [145] while the addition of
cuprizone promoted a significantly increase of prion PK resistance levels, suggesting that PrPC in the
apo form is more susceptible to PrPSc conversion [140].
The protective versus prion promoting effect of copper could depend on an array of variables that
are hard to untangle, which include, for instance, the status of the cholesterol metabolism that influence
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the Cu(II)-mediated PrPC endocytosis [63,146–148], the different copper chelators used to treat both
animal and cellular models (e.g., cuprizone versus d-penicillamine [116,121]), the homeostasis of
copper and other biometals binding PrPC, such as zinc and iron, during neurodegeneration [149–152]
and finally the different animal and cell culture models for prion diseases used to understand the role
of copper in disease progression.
Copper homeostasis is essential for normal physiology, as highlighted by the spectrum of diseases
caused by disruption of the copper transporting enzymes (e.g., Ctr1, and Atp7a) [153]. Notably, a first
Atp7a-mediated copper homeostasis link with prion diseases has been recently proposed. Authors
isolated by cross breading a mouse line (Atp7abrown) carrying a natural mutation in the Atp7a gene
(I483T) which is not linked to lethality but with reduced copper content in the brain. Interestingly, this
mutation significantly increased the incubation period of intracranial Rocky Mountain Laboratory
(RML) scrapie strain infection [154], supporting earlier reports that copper chelation can delay the
onset of TSE [121]. Nevertheless, the amount of neuronal loss and astrocytosis was similar in both
wild-type and Atp7abrown groups, indicating that even in the presence of reduced copper concentration
in the brain PrPSc remains capable of causing neurodegeneration and death [154].
A novel investigative approach could be the use of alternative animal models to dissect the role of
copper in prion diseases as naturally occurring rodent models for Menkes and Wilson diseases [155],
which may also provide new insights into the pathogenic changes related to copper dyshomeostasis in
TSE and other neurological disorders.
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